TELPLUS TRIO

About

Telplus Trio is a fixed-dose combination medication containing telmisartan, amlodipine, and hydrochlorothiazide, designed for the comprehensive management of hypertension. Telmisartan is an angiotensin II receptor blocker (ARB) that relaxes blood vessels by blocking the action of angiotensin II. Amlodipine is a dihydropyridine calcium channel blocker (CCB) that dilates both arterial and coronary blood vessels, further reducing blood pressure and improving blood flow. Hydrochlorothiazide is a thiazide diuretic that helps the body eliminate excess salt and water, which also contributes to blood pressure reduction. This triple combination targets multiple pathways involved in blood pressure regulation, making it effective for patients whose blood pressure is not adequately controlled by monotherapy or dual therapy. It provides a synergistic effect to achieve optimal blood pressure control and reduce cardiovascular risk.

Uses

• Treatment of essential hypertension.
• For patients whose blood pressure is not adequately controlled by dual therapy.
• To reduce the risk of cardiovascular events.
• As a convenient once-daily dosing option for complex hypertension.

Directions For Use

Take one tablet orally once daily, preferably at the same time each day, with or without food, as directed by your physician.

Benefits

• Potent and comprehensive blood pressure reduction.
• Targets multiple mechanisms of hypertension.
• Convenient once-daily dosing.
• Reduces the risk of cardiovascular complications.
• Effective for resistant hypertension.
• Improved patient adherence due to combination.

Side Effects

• Dizziness
• Headache
• Fatigue
• Peripheral edema (amlodipine)
• Hypotension
• Hyperkalemia (telmisartan)
• Hypokalemia (hydrochlorothiazide)
• Nausea
• Muscle cramps
• Increased urination (initially)
• Cough (rare)
• Rash

Safety Measures

• Alcohol - Alcohol can enhance the hypotensive effects of this combination, increasing the risk of dizziness and fainting. Avoid or limit consumption.
• Pregnancy - Contraindicated in pregnancy, especially during the second and third trimesters, due to potential fetal harm from telmisartan and hydrochlorothiazide.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk and potentially harm the infant.
• Liver - Use with caution in patients with severe liver impairment; dosage adjustments may be necessary, and it can exacerbate hepatic encephalopathy.
• Kidney - Use with caution in patients with severe renal impairment; monitor kidney function closely, as components can affect renal hemodynamics.
• Lung - Generally safe for use in patients with lung conditions, though hydrochlorothiazide should be used cautiously in patients with a history of allergy to sulfonamides.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.